RE: https://mstdn.social/@TechCrunch/116205018327360404

A reliable technology for returning payloads to Earth from #space 🌌 is a necessity for several futuristic business models β€” testing new materials in orbit, manufacturing #pharmaceuticals πŸ’Š or high-end #electronics in microgravity, or harvesting resources like metals from #asteroids.

Making satellites reusable ♻️ : "If you want to update a payload component every year, instead of having to build new #satellites πŸ›°οΈ and keep those old ones up in space, you can bring them down and go back"

Eli Lilly’s obesity drug retatrutide clears late-stage diabetes trial

The Eli Lilly logo appears on the company’s office in San Diego, California, U.S., Nov. 21, 2025. Mike…
#NewsBeep #News #Topstories #BiotechandPharmaceuticals #Biotechnology #BreakingNews:Business #Business #businessnews #EliLillyandCo #Headlines #Healthcareindustry #iSharesU.S.HealthcareETF #iSharesU.S.PharmaceuticalsETF #NovoNordiskA/S #Pharmaceuticals #TopStories
https://www.newsbeep.com/442200/

Africa: Pharma Pulls Back As Antimicrobial Resistance Threat Grows: [Independent (Kampala)] The rising threat of antimicrobial resistance (AMR) continues to expose deep structural weaknesses in global pharmaceutical markets, with drug-resistant infections projected to claim nearly two million lives annually by 2050 unless investment and policy responses accelerate, according to the 2026 AMR… http://newsfeed.facilit8.network/TRZg30 #AntimicrobialResistance #Pharmaceuticals #GlobalHealth #Healthcare #PublicHealth
Eli Lilly's breakthrough obesity drugs face hidden ESG risks: pricing ethics controversies, counterfeit markets, and supply chain weaknesses threaten its $800B valuation. Our analysis reveals what traditional investors miss. https://post.kapualabs.com/5n7npdx6 #ESGInvesting #Pharmaceuticals #StockAnalysis $LLY
The Cassandra analysis: Why Eli Lilly $LLY may be overvalued despite GLP-1 dominance. We examine 5 underappreciated risk vectors including structural pricing pressure, emerging safety concerns, and geopolitical concentration from their $3B China bet. https://post.kapualabs.com/333buajr #Contrarian #Pharmaceuticals #Investing $LLY
Eli Lilly navigates complex regulatory waters: upcoming FDA decisions, Medicare price negotiations under the Inflation Reduction Act, and patent battles with compounding pharmacies. Our analysis examines the risks and opportunities. https://post.kapualabs.com/2tu3smr8 #Pharmaceuticals #RegulatoryAffairs #Investing $LLY
Eli Lilly $LLY faces 8 critical risk dimensions threatening its GLP-1 obesity drug franchiseβ€”from cybersecurity vulnerabilities in digital distribution to next-generation oral competitors. Comprehensive risk assessment: https://post.kapualabs.com/2p9ervb8 #Pharmaceuticals #RiskAssessment #Investing #StockMarket
Eli Lilly's $800B GLP-1 success story conceals catastrophic tail risks that could trigger a 40-50% equity repricing. New analysis reveals three converging crises: illicit counterfeit markets, emerging safety signals, and inevitable margin compression. $LLY https://post.kapualabs.com/2eu6x2bz #Investing #Pharmaceuticals #RiskAnalysis #GLP1
Obesity drugs are revolutionizing Big Pharma. Eli Lilly $LLY leads with oral GLP-1 technology but faces significant pricing pressure from the Inflation Reduction Act. Our deep dive explores China expansion, manufacturing scale, and competitive moats: https://post.kapualabs.com/2p8kk5u5 #Pharmaceuticals #Biotech #Investing $LLY